期刊文献+

HPLC法测定抗心衰颗粒中黄芪甲苷的含量 被引量:3

Determination of Astragaloside Ⅳ in Kangxinshuai Granules by HPLC
暂未订购
导出
摘要 目的:用高效液相色谱法测定抗心衰颗粒中黄芪甲苷的含量。方法:以吡啶-苯甲酰氯(2.5:1)为衍生化试剂,采用Supelco ODS C_(18)柱(250mm×4.6 mm,5μm),流动相为甲醇-四氢呋喃-0.2%三乙胺水溶液(90:4:6),流速为1.2 ml·min^(-1),检测波长为230 nm。结果:黄芪甲苷衍生物进样量在0.03~0.93μg范围内与峰面积积分值呈良好线性关系(r=0.9999),平均加样回收率为95.17%,RSD=2.31%(n=6)。结论:该方法简便易行,结果准确,重复性好,可用于测定抗心衰颗粒中黄芪甲苷的含量。 Objective: To establish a method for the determination of astragaloside IV in Kangxinshuai granules by HPLC. Method: The derivatizing reagent was benzoyl chloride in pyridine ( 1: 2.5, V/V). The Supelco ODS C18 column (250 mm × 4.6 mm,5 μm) was used with methanol-tetrahydrofuran -0.2% triethylamine water solution(90: 4: 6) as the mobile phase. The flow rate was 1.2 ml· min^- 1, and the detection wavelength was at 230 nm. Result: The linear range of derivatization of astragaloside Ⅳ was 0.03 μg -0.93 μg ( r = 0. 999 9), the average recovery rate was 95.17% , and RSD was 2.31% ( n = 6). Conclusion: The method is simple, rapid, accurate and reproducible. It can be used for the content determination of astragaloside Ⅳ in Kangxinshuai Granules.
机构地区 江苏省中医院
出处 《中国药师》 CAS 2009年第7期910-912,共3页 China Pharmacist
基金 江苏省巾医药局基金项目(编号H05028)
关键词 抗心衰颗粒 黄芪甲苷 衍生化 高效液相色谱法 Kangxinshuai granules Astragaloside Ⅳ Derivatization HPLC
  • 相关文献

参考文献5

二级参考文献9

共引文献902

同被引文献25

  • 1张莲珠.HPLC测定黄芪甲苷概况[J].中成药,2005,27(5):587-589. 被引量:14
  • 2陈冲,倪志权,黄兴耀.自制蟾皮胶囊丸治疗原发性肝癌疗效观察[J].河南肿瘤学杂志,1996,9(1):40-42. 被引量:10
  • 3吴玉强,罗轶.HPLC-ELSD法测定复方扶芳藤合剂中黄芪甲苷[J].中草药,2006,37(9):1353-1354. 被引量:15
  • 4颜晓航.黄芪及其制剂中黄芪甲苷含量测定方法研究进展[J].安徽医药,2006,10(12):951-953. 被引量:24
  • 5国家食品药品监督管理局.国家药品标准[S].WS5635(B-0635)-2002.
  • 6J. George,A. D. Struthers,C. C. Lang.Modulation of the Renin-Angiotensin-Aldosterone System in Heart Failure[J]. Current Atherosclerosis Reports . 2014 (4)
  • 7Cho-Kai Wu,Jen-Kuang Lee,Fu-Tien Chiang.Impact of renin–Angiotensin system and inflammatory gene polymorphisms on diastolic heart failure[J]. Journal of the Formosan Medical Association . 2012
  • 8Sayer G,Bhat G.The renin-angiotensin-aldosterone system and heart failure. Cardiology Clinics . 2014
  • 9Moon JY.Recent update of renin-angiotensin-aldosterone system in the pathogenesis of hypertension. Electrolyte Blood Press . 2013
  • 10ri K,Fagyas M,MányinéSiket I,Kertész A,Csanádi Z,Sándorfi G,Clemens M,Fedor R,Papp Z,édes I,Tóth A,Lizanecz E.New perspectives in the renin-angiotensin-aldosterone system (RAAS)IV:circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure. PLo S One . 2014

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部